Navigation Links
Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
Date:3/30/2008

Arterial renarrowing less likely, with no increase in mortality on

long-term follow-up

CHICAGO, March 30 /PRNewswire/ -- Although drug-eluting stents have become widely used for the treatment of stable coronary artery disease, many cardiologists choose bare-metal stents for patients with heart attack, or myocardial infarction (MI), citing conflicting data about the safety and effectiveness of drug-eluting stents in this patient group. Such concerns are being challenged by an analysis of a large Massachusetts database.

The analysis showed a significantly lower risk of arterial renarrowing, or restenosis, among heart attack patients who were treated with drug-eluting stents, with no increase in mortality, when compared to those treated with bare-metal stents.

The study is being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

"This study confirms that the same benefits that drug-eluting stents offer other patients in preventing restenosis of the coronary arteries are still there for patients with MI, and there doesn't appear to be any trade-off in increased risk of repeat MI or death," said Laura Mauri, MD, MSC, an interventional cardiologist at Brigham and Women's Hospital, an assistant professor of medicine at Harvard Medical School, and chief scientific officer at the Harvard Clinical Research Institute, all in Boston.

Cardiologists have had to decide which type of stent to use in heart attack patients based on small randomized trials that didn't include long-term follow-up and reported conflicting results. There have also been concerns that, because heart attack pa
'/>"/>

SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
5. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
6. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
7. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
8. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
9. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
10. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
11. Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 1Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 1Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 3Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 4Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 1Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 2
Other Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 2Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 3Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 4Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 5
Other Medicine News:Health News:Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets 2Health News:Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets 3Health News:Pill Could Boost Sports Performance 2Health News:Get Straight A's in Snacking with Supercharged Superfruits from Fruitaceuticals! 2Health News:'Who's Who' Weight Specialist Martin Schiff, M.D., 86, Devoting Rest of Life to Spreading Truth About Diets, Won't Accept Compensation From Anyone, Sending Complete Guide Free to All 2Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 2Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 3Health News: Freescale and Monebo Launch ECG-on-a-Chip Platform Solution to Aid Heart Monitoring : Advanced Hardware and Software Technology Designed to Enable More Efficient and Higher Quality Cardiac Care 2